Short answer: Both are Russian-developed seven-amino-acid peptides.1 Semax is built on an ACTH fragment and studied mainly for stroke;2 selank is a tuftsin analog studied for anxiety.3 Human data are thin: PubMed tags only 4 semax and 3 selank records as clinical trials, mostly in Russian-language journals.45 Neither is approved in the US.
| Semax | Selank | |
|---|---|---|
| What it is | Heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro: ACTH(4-7) plus Pro-Gly-Pro2 | Heptapeptide analog of tuftsin, an immune peptide13 |
| Main studied use | Ischemic stroke recovery6 | Anxiety disorders7 |
| Proposed mechanism | Raised blood BDNF in a stroke study6 | GABA receptor modulation in lab studies1 |
| PubMed records tagged as trials | 4 (October 2026)4 | 3 (October 2026)5 |
| Example human study | 110 stroke patients; two 10-day courses of 6,000 mcg/day6 | 62 patients with anxiety or neurasthenia vs medazepam;7 60 patients vs phenazepam8 |
| Half-life | No published human value | No published human value |
| US status | Not approved. Nominated but withdrawn from FDA Category 29 | Not approved. Nominated but withdrawn from FDA Category 29 |
| FDA advisory committee 2026 | Reviewed July 24, 2026 (cerebral ischemia, migraine, trigeminal neuralgia)10 | Not on the July 2026 agenda10 |
Both are seven amino acids long. Semax is Met-Glu-His-Phe, a piece of ACTH (the stress hormone that drives cortisol), followed by Pro-Gly-Pro.2 It is described as a nootropic rather than a hormone.11 Selank is built on tuftsin, a short immune-system peptide.3 Lab studies suggest selank acts on GABA receptors, the same system targeted by benzodiazepines.1
Very little that is easy to check. On October 22, 2026, PubMed tagged only 4 semax and 3 selank records as clinical or randomized trials,45 and most human studies are in Russian-language journals, so we could read only their English abstracts.
A 2021 US pharmacology review described selank as a "poorly studied" Russian drug sold to US consumers as a supplement.12 These are study protocols, not personalized advice; confirm any dosing with your prescriber.
Neither is approved in the US. Both are on FDA's list of compounding substances that were in Category 2 and then withdrawn by their nominators; FDA says it lacks safety information for the proposed routes.9 FDA's advisory committee reviewed semax on July 24, 2026 for cerebral ischemia, migraine and trigeminal neuralgia; selank was not on the agenda.10